IP Library Granted Patent US 11,754,565
Granted Patent B2
US 11,754,565 · App. 16/386,327 · Granted Sep 12, 2023

Methods and kits for quantifying the removal of mock virus particles from a purified solution

Inventors: David Cetlin (Potomac, MD); Arun Dhar (Tucson, AZ)
Assignee: MOCKV SOLUTIONS LLC
G01N33/56983A61K39/12A61K39/23A61K39/21A61K2039/5258C12N2740/10023C12N2750/14023C12Q1/701C12Q2600/158G01N2333/015G01N2333/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,754,565
App. No.
16/386,327
Granted
Sep 12, 2023
Kind
B2
Abstract

The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.

Claims (9)

1. A kit comprising:

a stock solution comprising a modified Mouse Minute Virus (MMV) Mock Viral Particle (MVP), wherein the MMV MVP is a non-infectious, non-replicating assembled unit comprising a MMV VP2 viral capsid protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 6, wherein said stock solution comprises at least 1×10 10 MMV MVP/ml of said MMV MVP and wherein non-MMV MVP proteins are less than 25% of all proteins in the stock solution.

2. The kit of claim 1 , wherein said viral capsid protein is produced in a bacterium, yeast, plant, insect cell, animal or human cell.

3. The kit of claim 1 , wherein non-MMV MVP proteins are less than 5% of all proteins in the stock solution.

4. The kit of claim 1 , wherein the MMV MVP does not comprise a MMV VP1 viral capsid protein.

5. The kit of claim 1 , wherein the MMV VP2 viral capsid protein is encoded by a nucleic acid comprising SEQ ID NO: 5.

6. The kit of claim 1 , wherein the MMV VP2 capsid protein comprises SEQ ID NO: 6.

7. The kit of claim 1 , wherein the kit further comprises an antibody that specifically binds to the MMV VP2 capsid protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 6.

8. The kit of claim 6 , wherein the kit further comprises an antibody that specifically binds to SEQ ID NO: 6.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: MOCKV SOLUTIONS LLC
To: CYGNUS TECHNOLOGIES, LLC
Reel/Frame 069609/0917 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 048915 FRAME: 0925. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 14, 2023
From: CETLIN, DAVID; DHAR, ARUN
To: MOCKV SOLUTIONS LLC
Reel/Frame 064466/0031 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SHOULD BE LISTED AS MOCKV SOLUTIONS LLC. PREVIOUSLY RECORDED AT REEL: 048915 FRAME: 0925. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 22, 2022
From: CETLIN, DAVID; DHAR, ARUN
To: MOCKV SOLUTIONS LLC
Reel/Frame 061508/0842 →
SECURITY AGREEMENT Recorded Oct 19, 2020
From: MARAVAI LIFE SCIENCES, INC.; TRILINK BIOTECHNOLOGIES, LLC; VECTOR LABORATORIES, INC.; GLEN RESEARCH, LLC; CYGNUS TECHNOLOGIES, LLC; MOCKV SOLUTIONS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 054118/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2019
From: CETLIN, DAVID; DHAR, ARUN
To: MOCKV SOLUTIONS
Reel/Frame 048915/0925 →
Cited By (1)
US 12,553,894